China News Service, May 25th (Sun Guogen, Chen Jing) After three years of research, Chinese medical experts have discovered and verified the "super soldier" against tumor cells in the gastric cancer microenvironment, improving the prognosis prediction model and immunotherapy for gastric cancer patients The individualized choice provides a new direction.
The scientific research team of Professor Xu Jiejie, School of Basic Medicine, Fudan University, found that CXCR5+CD8+ T cells can be used as a new prognostic marker and potential immunotherapy target for gastric cancer patients in a large sample of gastric cancer patients and four cohorts (from different clinical centers) And a guiding factor for individualized medication.
Relevant research results were published on the 25th in the international academic journal "Nature" magazine "Nature Communications" ("Nature Communications").
In an interview with reporters, Xu Jiejie introduced that the early symptoms of gastric cancer are not obvious, and many patients are already in the advanced stage when they are first diagnosed.
Although standard radical gastric cancer surgery and postoperative chemotherapy can bring certain survival benefits to gastric cancer patients, the prognosis of most patients is still not optimistic.
Therefore, it is of great significance to discover new markers of gastric cancer treatment response, so as to achieve precise medical treatment of gastric cancer patients.
It is understood that in recent years, by intervening in the tumor immune microenvironment and the patient's immune system, achieving sustained anti-tumor effects has become an important means of treating advanced tumors.
Xu Jiejie pointed out that exploring new immunotherapy targets to improve the quality of life of patients with gastric cancer has become an important clinical problem that urgently needs to be resolved.
The research team found that CXCR5+CD8+ T cell expression has a "immune brake" checkpoint molecule that is "particularly capable of fighting".
The more cells of this group of "super soldiers" indicate that the patient has a longer overall survival time, and confirms that the patient has a better response to postoperative adjuvant chemotherapy or chemotherapy combined with radiotherapy.
Relevant conclusions have been confirmed in four cohort studies of gastric cancer patients.
(Finish)